Outcomes and complications after splenectomy for hematologic disorders

Area of Science:

• Hematology
• Surgical Oncology
• Immunology

Background:

• Splenectomy is a second-line treatment for immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AHA) resistant to medical management.
• Evaluating splenectomy outcomes is crucial for refractory ITP and AHA cases.

Purpose of the Study:

• To assess the effectiveness and outcomes of splenectomy in patients with ITP and AHA.
• To determine the response rates and complication profiles associated with splenectomy for these hematologic disorders.

Main Methods:

• Retrospective review of medical records for patients who underwent splenectomy for ITP or AHA between January 1, 1996, and December 31, 2010.
• Analysis of patient demographics, initial response, relapse rates, and long-term complications.

Main Results:

• Out of 60 patients (45 ITP, 15 AHA), initial complete response rates were 91% for ITP and 93% for AHA.
• Relapse occurred in 17% of ITP and 29% of AHA patients, with an overall sustained complete response rate of 85% (82% ITP, 93% AHA).
• Thirty-day and long-term complication rates were 10% and 5%, respectively, with no perioperative mortality.

Conclusions:

• Splenectomy demonstrates favorable response rates and low morbidity in managing ITP and AHA.
• It serves as an effective adjunct therapy for patients unresponsive to or relapsing after medical treatments.